Delayed and Sustained Activation of p42/p44 Mitogen‐Activated Protein Kinase Induced by Proteasome Inhibitors Through p21ras in PC12 Cells

• Published in: Journal of neurochemistry Vol. 74; no. 1; pp. 92 - 98
• Main Authors: Hashimoto, Keiko, Guroff, Gordon, Katagiri, Yasuhiro
• Format: Journal Article
• Language: English
• Published: Oxford UK Blackwell Science Ltd 01.01.2000; Blackwell
• Subjects: Biological and medical sciences; Cell physiology; Fundamental and applied biological sciences. Psychology; Mitogen‐activated protein kinase; Molecular and cellular biology; Nerve growth factor; PC12 cells; Proteasome; Signal transduction; Multicatalytic endopeptidase complex; Enzyme; Transferases; Enzyme inhibitor; Nerve growth factor; In vitro; Peptidases; Signal transduction; Cell line; Neuron; Protein kinase; Hydrolases; Mitogen
• ISSN: 0022-3042; 1471-4159
• DOI: 10.1046/j.1471-4159.2000.0740092.x

: Proteolysis by the ubiquitin/proteasome pathway regulates the intracellular level of several proteins, some of which control cell proliferation and cell cycle progression. To determine what kinds of signaling cascades are activated or inhibited by proteasome inhibition, we treated PC12 cells with specific proteasome inhibitors and subsequently performed in‐gel kinase assays. N‐Acetyl‐Leu‐Leu‐norleucinal and lactacystin, which inhibit the activity of the proteasome, induced the activation of p42/p44 mitogen‐activated protein (MAP) kinases [extracellular signal‐regulated kinases (ERKs) 1 and 2]. In contrast, N‐acetyl‐Leu‐Leu‐methional, which inhibits the activity of calpains, but not of the proteasome, failed to induce ERK activation. Uniquely, the kinetics of MAP kinase activation induced by proteasome inhibitors are very slow compared with those resulting from activation by nerve growth factor; ERK activation is detectable only after a 5‐h treatment with the inhibitors, and its activity remained unchanged for at least until 27 h. Proteasome inhibitor‐initiated ERK activation is inhibited by pretreatment with the ERK kinase inhibitor PD 98059, as well as by overexpression of a dominant‐negative form of Ras. Thus, proteasome inhibitors induce sustained ERK activation in a Ras‐dependent manner. Proteasome inhibitor‐induced neurite outgrowth, however, is not inhibited by PD 98059, indicating that sustained activation of ERKs is not the factor responsible for proteasome inhibitor‐induced morphological differentiation. Our data suggest the presence of a novel mechanism for activation of the MAP kinase cascade that involves proteasome activity.